Postrenal transplantation diabetes mellitus (PTDM), or new-onset diabetes after organ transplantation, is an important chronic transplant-associated complication. Similar to type 2 diabetes, decreased insulin secretion and increased insulin resistance are important to the pathophysiologic mechanism behind the development of PTDM. However, β-cell dysfunction rather than insulin resistance seems to be a greater contributing factor in the development of PTDM. Increased age, family history of diabetes, ethnicity, genetic variation, obesity, and hepatitis C are partially accountable for an increased underlying risk of PTDM in renal allograft recipients. In addition, the use of and kinds of immunosuppressive agents are key transplant-associated risk factors. Recently, a number of genetic variants or polymorphisms susceptible to immunosuppressants have been reported to be associated with calcineurin inhibition-induced β-cell dysfunction. The identification of high risk factors of PTDM would help prevent PTDM and improve long-term patient outcomes by allowing for personalized immunosuppressant regimens and by managing cardiovascular risk factors.

Citations

Citations to this article as recorded by  

• Risk Factors Related to New-Onset Diabetes after Renal Transplantation in Patients of a High Complexity University Hospital in Colombia, 20 Years of Experience
  Guillermo E. Guzmán, Angela M. Victoria, Isabella Ramos, Alejandro Maldonado, Eliana Manzi, Juan F. Contreras-Valero, Liliana Mesa, Johanna Schweineberg, Juan G. Posada, Jorge I. Villegas, Luis A. Caicedo, Carlos E. Durán
  International Journal of Endocrinology.2020; 2020: 1.     CrossRef
• Synthesis of Fructose Biosensors and Progressing Their Efficiency Using Californium Colloidal Nanoparticles for Detecting Fructose and Triglycerides
  Alireza Heidari
  Advanced Science, Engineering and Medicine.2020; 12(8): 1002.     CrossRef
• Comparison of Glucose Tolerance between Kidney Transplant Recipients and Healthy Controls
  Hisao Shimada, Junji Uchida, Shunji Nishide, Kazuya Kabei, Akihiro Kosoku, Keiko Maeda, Tomoaki Iwai, Toshihide Naganuma, Yoshiaki Takemoto, Tatsuya Nakatani
  Journal of Clinical Medicine.2019; 8(7): 920.     CrossRef
• Diabètes post-transplantation rénale
  Danièle Dubois-Laforgue
  Néphrologie & Thérapeutique.2017; 13: S137.     CrossRef
• Risk assessment and management of post-transplant diabetes mellitus
  Eugene Han, Myoung Soo Kim, Yu Seun Kim, Eun Seok Kang
  Metabolism.2016; 65(10): 1559.     CrossRef
• Renal posttransplantation diabetes mellitus: An overview
  Ana Laura Pimentel, Andrea Carla Bauer, Joíza Lins Camargo
  Clinica Chimica Acta.2015; 450: 327.     CrossRef
• HMG CoA Reductase Inhibitor Treatment Induces Dysglycemia in Renal Allograft Recipients
  Eun Yeong Choe, Hye Jin Wang, Obin Kwon, Yongin Cho, Kyu Ha Huh, Myoung Soo Kim, Yu Seun Kim, Chul Woo Ahn, Bong Soo Cha, Hyun Chul Lee, Eun Seok Kang
  Transplantation.2014; 97(4): 419.     CrossRef
• Statin therapy is associated with the development of new-onset diabetes after transplantation in liver recipients with high fasting plasma glucose levels
  Yongin Cho, Min Jung Lee, Eun Yeong Choe, Chang Hee Jung, Dong Jin Joo, Myoung Soo Kim, Bong Soo Cha, Joong-Yeol Park, Eun Seok Kang
  Liver Transplantation.2014; 20(5): 557.     CrossRef
• Post-Transplant Diabetes Mellitus: Is It Associated With Poor Allograft Outcomes in Renal Transplants?
  J.Y. Choi, O.J. Kwon
  Transplantation Proceedings.2013; 45(8): 2892.     CrossRef